Karolinska Development: Our view to clinical advancement of Forendo project
Research Note
2019-03-07
15:15
Earlier today, Karolinska Development (KD) announced that their portfolio company, Forendo Pharma, has advanced in the clinic with their lead candidate, FOR-6219. It is positive news per se and represents an upside opportunity as this project is currently not included in our valuation.
AH
Anders Hedlund
Disclosures and disclaimers